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ABSTRACT 
PURPOSE: To verify if the methylene blue (MB) administration prevents and/or reverses the compound 48/80 (C48/80)-induced 
anaphylactic shock in pigs. 
METHODS: Female Dalland pigs were anesthetized and had the hemodynamic parameters recorded during the necessary time to 
administer some drugs and observe their effect. The animals were randomly assigned to one of the five groups: 1) control; 2) MB: 
the animals received a bolus injection of MB (2 mg/kg) followed by continuous infusion of MB (2.66 mg/Kg/h delivered by syringe 
infusion pump); 3) C48/80: the animals received a bolus injection of C48/80 (4 mg/kg); 4) C48/80+MB: the animals received a bolus 
injection of C48/80 (4 mg/kg) and 10 minutes after the C48/80 administration the animals received a bolus injection of MB (2 mg/kg) 
followed by continuous infusion of MB (2.66 mg/Kg/h delivered by syringe infusion pump); 5) MB+C48/80: the animals received a 
bolus injection of MB (2 mg/kg) and 3 minutes later they received a bolus injection of C48/80 (4 mg/kg). 
RESULTS: The intravenous infusion of MB alone caused no changes in the mean arterial pressure (MAP) showing that the administered 
MB dose was safe in this experimental model. The C48/80 was effective in producing experimental anaphylactic shock since it was 
observed a decrease in both MAP and cardiac output (CO) after its administration. The MB did not prevent or reverse the C48/80-
induced anaphylactic shock in this model. In fact, the MAP of the animals with anaphylactic shock treated with MB decreased even 
more than the MAP of the animals from the C48/80 group. On the other hand, the C48/80-induced epidermal alterations disappeared 
after the MB infusion.
CONCLUSION: Despite our data, the clinical manifestations improvement brings some optimism and does not allow excluding the 
MB as a possible therapeutic option in the anaphylactic shock.
Keywords: Nitric Oxide. Methylene Blue. Anaphylaxis. Guanylate Cyclase. Swine.
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RESUMO
OBJETIVO: Verificar se a administração de azul de metileno (AM) previne e/ou reverte o choque anafilático induzido por composto 
48/80 (C48/80) em suínos. 
MÉTODOS: Porcos fêmeas Dalland foram anestesiados e tiveram os parâmetros hemodinâmicos registados durante o tempo necessário 
para administrar algumas drogas e observar seu efeito. Os animais foram aleatoriamente destribuídos em um dos cinco grupos: 1) 
controle, 2) AM: os animais receberam uma injeção em bolus de AM (2mg/kg), seguido de infusão contínua de AM (2,66mg/Kg /h por 
bomba de infusão de seringa); 3) C48/80: os animais receberam uma injeção em bolus de C48/80 (4mg/kg); 4) C48/80 + AM: os animais 
receberam uma injeção em bolus de C48/80 (4mg/kg) e 10 minutos após a administração de C48/80 os animais receberam uma injeção 
em bolus de AM (2mg/kg), seguido de infusão contínua de AM (2,66mg/kg/h por bomba de infusão de seringa); 5) AM+C48/80: os 
animais receberam uma injeção em bolus de AM (2mg/kg) e três minutos depois, receberam uma injeção em bolus de C48/80 (4mg/kg). 
RESULTADOS: A infusão intravenosa de AM não causou mudanças na pressão arterial média (PAM), mostrando que a dose de AM 
administrada foi segura neste modelo experimental. O C48/80 foi eficaz na indução do choque anafilático experimental, uma vez que 
foi observada redução na PAM e débito cardíaco (DC), após a sua administração. O AM não preveniu ou reverte o choque anafilático 
induzido por C48/80 neste modelo. Na verdade, a PAM dos animais com choque anafilático tratados com AM diminuiu mais do que o 
PAM dos animais do grupo C48/80. Por outro lado, as alterações epidérmicas induzidas pelo C48/80 desapareceu após a infusão do AM.
CONCLUSÃO: Apesar dos resultados a melhora clínica das manifestações anafiláticas permite considerar a possibilidade do azul de 
metileno como opção terapêutica no tratamento do choque anafilático.
Descritores: Óxido Nítrico. Azul de Metileno. Anafilaxia. Guanilato Ciclase. Suínos.
Introduction
It is currently known that nitric oxide (NO) is associated 
with vasoplegic reactions in sepsis1-11, anaphylaxis12-17 and 
cardiopulmonary bypass related systemic inflammatory response 
syndrome (SIRS). NO is a powerful endogenous vasodilatator. 
The nitric oxide synthases (NOS) are the enzymes responsible 
for converting L-arginine in NO and L-citrulline. Experimental 
studies in rabbits demonstrated that the NOS inhibition by 
L-arginine analogs reverses anaphylactic hypotension18. But, these 
inhibitors cause cardiac output decrease and pulmonary vascular 
resistance increase13,14,19. Also, it is important to emphasize that 
L-arginine analogs inhibit both endothelial (eNOS) and inducible 
(iNOS) NOS isoforms. The ideal would be inhibit specifically the 
iNOS, which is responsible for vasoplegic reactions, preserving 
the eNOS activity, which has a vital role for the microcirculation 
physiology1,13. The NO synthesis inhibition is still a matter of 
controversy and, even a matter of bioethics. So, the blockade 
of the NO effects on the vascular smooth muscle, via guanylyl 
cyclase (GC) inhibition, would be a reasonable strategy20. The 
GC increases the cyclic guanosine 3’,5’-monophosphate (cGMP) 
levels promoting vasodilation. In some studies, the methylene 
blue (MB), a GC inhibitor, reversed the anaphylactic shock16,17,21. 
Since these studies involved a small number of patients, the 
MB effectiveness and safety have been questioned. Therefore, 
the present study aimed to verify if the MB administration 
prevents and/or reverses the compound 48/80 (C48/80)-induced 
anaphylactic shock in pigs.
 
Methods
Animal preparation and hemodynamic parameters
Female Dalland pigs (22-26 kg) were induced to 
anesthesia with intramuscular administration of midazolan (15 
mg/kg, Dormid®, Cristália Produtos Químicos Ltda., SP, Brazil) 
and tiletamine/zolazepam (10 mg/kg, Telazol®, Fort Dodge, IA, 
EUA). Maintenance was achieved by total intravenous anesthesia 
using sulfentanyl (100 μg/h, Fastfan®, Cristália Produtos Químicos 
Ltda., SP, Brazil) and propofol (10 mg/Kg/h, Propovan®, Cristália 
Produtos Químicos Ltda., SP, Brazil) delivered by syringe 
infusion pump (Syringe Infusion Pump, Harvard Apparatus, 
MA, EUA). Pancuronium bromide (6 mg/h, Pancuron®, 
Cristália Produtos Químicos Ltda., SP, Brazil) was used as a 
muscular relaxant. Tracheostomy was performed on all animals 
immediately after induction of anesthesia. Volemia maintenance 
was achieved with intravenous infusion of sodium chloride 0.9% 
(5 mL/kg/h). A Swan-Ganz CCOmbo CCO/SvO2 744HF75 
(Edwards Lifesciences, CA, EUA) catheter was placed in the right 
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jugular vein and into the lumen of the main pulmonary artery. 
The left carotid was simultaneously catheterized. Mean arterial 
pressure (MAP), pulmonary arterial pressure (PAP), pulmonary 
capillary pressure (PCP) and central venous pressure (CVP) were 
recorded by the MP System 100 A (BioPac System, Inc., CA, 
EUA). Cardiac output (CO), systemic vascular resistance (SVR) 
and pulmonary vascular resistance (PVR) were obtained by the 
Vigilance System (Edwards Lifesciences LLC, CA, EUA). After 
instrumentation, a period of 20 minutes was allowed for anesthesia 
stabilization. After that, the hemodynamic parameters and the 
clinical condition were recorded for 15 minutes. 
Experimental design 
The animals (n=30) were randomly assigned to one of 
the five groups: 
1. control: the animals received the same volume of the 
vehicle used to prepare the drugs in the other groups at the same 
time points; 
2. MB: immediately after the 20 minutes stabilization 
the animals received a bolus injection of MB (2 mg/kg) followed 
by continuous infusion of MB (2.66 mg/Kg/h delivered by syringe 
infusion pump); 
3. C48/80: immediately after the 20 minutes stabilization 
the animals received a bolus injection of C48/80 (4 mg/kg); 
4. C48/80+MB: immediately after the 20 minutes 
stabilization the animals received a bolus injection of C48/80 
(4 mg/kg) and 10 minutes after the C48/80 administration the 
animals received a bolus injection of MB (2 mg/kg) followed by 
continuous infusion of MB (2.66 mg/Kg/h delivered by syringe 
infusion pump);
5. MB+C48/80: immediately after the 20 minutes 
stabilization the animals received a bolus injection of MB (2 mg/
kg) and 3 minutes later they received a bolus injection of C48/80 
(4 mg/kg).
Statistical analysis
The results are expressed as mean ± standard error of the 
mean (SEM) and were analyzed using analysis of variance (one-
way ANOVA) and Bonferroni post-test (Prism 4.0, GraphPad 
Software Inc., San Diego, CA, USA). Values were considered to 
be statistically significant at p values smaller than 0.05. 
Results
Clinical observations 
There were no clinical alterations after MB injection in 
the MB group. 
Five from six animals in the C48/80 group presented 
cutaneous hyperemia, vomits and sphincters liberation 
approximately 2 minutes after the injection of this compound. 
Livedo reticularis and cyanosis appeared a little bit later, persisting 
until the end of the experiment, when ascites and intestinal 
ischemia and distention were also observed.
Four from six animals in the C48/80+MB group presented 
cutaneous hyperemia, vomits and sphincters liberation about two 
minutes after the C48/80 administration, but after the MB infusion 
the epidermal alterations disappeared, and there was an apparent 
better peripheral perfusion. 
None of the six animals in the MB+C48/80 group 
presented clinical changes after the MB injection, but all of 
them presented cutaneous hyperemia (which decreased slow in 
two animals) and five of them presented vomits and sphincters 
liberation after C48/80 administration. 
Hemodynamic observations 
Mean arterial pressure (MAP) 
Only one animal in the MB group had, immediately 
after MB injection, an increase in MAP which was spontaneously 
normalized in about 10 minutes. However, there were no changes 
in MAP between the control and the MB groups, showing that 
the administered MB dose was safe in this experimental model 
(Figure 1A). 
The C48/80 group presented a hypotension which was 
statistically significant from 5th to 14th minute in the comparison 
with the control group (Figure 1A). 
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FIGURE 1A - Mean arterial pressure (MAP) in the control, methylene 
blue (MB) and compound 48/80 (C48/80) groups. All values are means 
± SEM (n=6 in each group) and represent the MAP variation (ΔMAP 
= MAPt – MAPt=0) in each time point (t varies from 0 to 15 minutes). * 
p<0.05, # p<0.01 in the comparison between control and C48/80 (One-
way ANOVA, Bonferroni’s Multiple Comparison Test).
The C48/80+MB group presented a larger decrease in the 
MAP than the C48/80 group with statistical difference between the 
6th and the 9th minute (Figure 1B).
There were no differences between the C48/80 and 
MB+C48/80 (Figure 1B).  
FIGURE 1B - Mean arterial pressure (MAP) in the compound 48/80 
(C48/80), C48/80 followed by methylene blue (C48/80+MB) and 
methylene blue followed by C48/80 (MB+C48/80) groups. All values 
are means ± SEM (n=6 in each group) and represent the MAP variation 
(ΔMAP = MAPt – MAPt=0) in each time point (t varies from 0 to 15 
minutes). * p<0.05 in the comparison between control and C48/80 (One-
way ANOVA, Bonferroni’s Multiple Comparison Test).
Pulmonary arterial pressure (PAP) 
The control group presented a stable PAP (Figure 2A). 
In the MB group, the PAP decreased a little from 5th to 
7th minute, but it was completely recovered in the 12nd minute. 
However, these differences did not reach statistical significance in 
comparison to the control group (Figure 2A). 
FIGURE 2A - Pulmonary arterial pressure (PAP) in the control, methylene 
blue (MB) and compound 48/80 (C48/80) groups. All values are means 
± SEM (n=6 in each group) and represent the PAP variation (ΔPAP = 
PAPt – PAPt=0) in each time point (t varies from 0 to 15 minutes). * p<0.05 
in the comparison between control and C48/80 (One-way ANOVA, 
Bonferroni’s Multiple Comparison Test).
The C48/80 group presented a lung hypertension in the 
beginning of the experiment (statistically significant in the 2nd and 
3rd minutes compared to the control group) returning to the basal 
levels in the 4th minute (Figure 2B). 
There were no statistical differences between the C48/80 
and the C48/80+MB or MB+C48/80 (Figure 2B). 
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FIGURE 2B - Pulmonary arterial pressure (PAP) in the compound 
48/80 (C48/80), C48/80 followed by methylene blue (C48/80+MB) and 
methylene blue followed by C48/80 (MB+C48/80) groups. All values are 
means ± SEM (n=6 in each group) and represent the PAP variation (ΔPAP 
= PAPt – PAP0) in each time point (t varies from 0 to 15 minutes).
Pulmonary capillary pressure (PCP)
Except for the 1st minute when the C48/80 showed an 
increase in the PCP compared to the control group, there were no 
statistical differences between the control and the MB or C48/80 
(Figure 3A).
FIGURE 3A - Pulmonary capillary pressure (PCP) in the control, 
methylene blue (MB) and compound 48/80 (C48/80) groups. All values 
are means ± SEM (n=6 in each group) and represent the PCP variation 
(ΔPCP = PCPt – PCPt=0) in each time point (t varies from 0 to 15 minutes). 
* p<0.05 in the comparison between control and C48/80 (One-way 
ANOVA, Bonferroni’s Multiple Comparison Test).
In the same way, it can be observed a statistically 
increase in the PCP only in the 9th minute for the MB+C48/80 
in comparison to the C48/80 group, without any other difference 
between the C48/80 and the C48/80+MB or MB+C48/80 (Figure 
3B).
FIGURE 3B - Pulmonary capillary pressure (PCP) in the compound 
48/80 (C48/80), C48/80 followed by methylene blue (C48/80+MB) and 
methylene blue followed by C48/80 (MB+C48/80) groups. All values 
are means ± SEM (n=6 in each group) and represent the PCP variation 
(ΔPCP = PCPt – PCPt=0) in each time point (t varies from 0 to 15 minutes). 
* p<0.05 in the comparison between control and C48/80 (One-way 
ANOVA, Bonferroni’s Multiple Comparison Test).
Central venous pressure (CVP)
There were no changes in the CVP values between the 
control and the MB or C48/80 groups (Figure 4A), neither between 
the C48/80 and the C48/80+MB or MB+C48/80 (Figure 4B).
FIGURE 4A - Central venous pressure (CVP) in the control, methylene 
blue (MB) and compound 48/80 (C48/80) groups. All values are means ± 
SEM (n=6 in each group) and represent the CVP variation (ΔCVP = CVPt 
– CVP
t=0
) in each time point (t varies from 0 to 15 minutes). 
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FIGURE 4B - Central venous pressure (CVP) in the compound 48/80 
(C48/80), C48/80 followed by methylene blue (C48/80+MB) and 
methylene blue followed by C48/80 (MB+C48/80) groups. All values are 
means ± SEM (n=6 in each group) and represent the CVP variation (ΔCVP 
= CVPt – CVPt=0) in each time point (t varies from 0 to 15 minutes). 
Cardiac output (CO)
The control group demonstrated a stable CO and the 
MB group did not differ from it. The C48/80 group presented a 
statistically significant decrease in the CO from 8th to 15th minute 
compared to the control group (Figure 5A). 
The CO of both C48/80+MB and MB+C48/80 groups 
were not different from the control group (Figure 5B).
FIGURE 5A - Cardiac output (CO) in the control, methylene blue (MB) 
and compound 48/80 (C48/80) groups. All values are means ± SEM (n=6 
in each group) and represent the CO variation (ΔCO = COt – CO t=0) in 
each time point (t varies from 0 to 15 minutes). * p<0.05, # p<0.001 in the 
comparison between control and C48/80 (One-way ANOVA, Bonferroni’s 
Multiple Comparison Test).
FIGURE 5B - Cardiac output (CO) in the compound 48/80 (C48/80), 
C48/80 followed by methylene blue (C48/80+MB) and methylene blue 
followed by C48/80 (MB+C48/80) groups. All values are means ± SEM 
(n=6 in each group) and represent the CO variation (ΔCO = COt – COt=0) 
in each time point (t varies from 0 to 15 minutes).
Systemic vascular resistance (SVR) 
Except for the 2nd minute when the C48/80 demonstrated 
an increase in the SVR compared to the control group, there 
were no statistical differences between the control and the MB or 
C48/80 (Figure 6A).
Comparing the SVR values, there were no statistical 
differences between the C48/80 and the C48/80+MB or 
MB+C48/80 (Figure 6B). 
FIGURE 6A - Systemic vascular resistance (SVR) in the control, 
methylene blue (MB) and compound 48/80 (C48/80) groups. All values 
are means ± SEM (n=6 in each group) and represent the SVR variation 
(ΔSVR = SVRt – SVRt=0) in each time point (t varies from 0 to 15 
minutes). * p<0.05 in the comparison between control and C48/80 (One-
way ANOVA, Bonferroni’s Multiple Comparison Test).
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FIGURE 6B - Systemic vascular resistance (SVR) in the compound 
48/80 (C48/80), C48/80 followed by methylene blue (C48/80+MB) and 
methylene blue followed by C48/80 (MB+C48/80) groups. All values are 
means ± SEM (n=6 in each group) and represent the SVR variation (ΔSVR 
= SVRt – SVRt=0) in each time point (t varies from 0 to 15 minutes).
Pulmonary vascular resistance (PVR)
The control group demonstrated a stable PVR. Although 
the other groups showed not a stable, but a variable PVR, there 
were no statistical differences between the control versus MB or 
C48/80 (Figure 7A) and between the C48/80 versus C48/80+MB 
or MB+C48/80 (Figure 7B). 
FIGURE 7A - Pulmonary vascular resistance (PVR) in the control, 
methylene blue (MB) and compound 48/80 (C48/80) groups. All values 
are means ± SEM (n=6 in each group) and represent the PVR variation 
(ΔPVR = PVRt – PVRt=0) in each time point (t varies from 0 to 15 minutes).
FIGURE 7B - Pulmonary vascular resistance (PVR) in the compound 
48/80 (C48/80), C48/80 followed by methylene blue (C48/80+MB) and 
methylene blue followed by C48/80 (MB+C48/80) groups. All values are 
means ± SEM (n=6 in each group) and represent the PVR variation (ΔPVR 
= PVRt – PVRt=0) in each time point (t varies from 0 to 15 minutes).
Discussion
The C48/80 has been used to produce experimental 
anaphylactic shock18,22. Our data showed that this compound 
was effective in inducing anaphylactic shock in pigs since both 
MAP and CO decreased after C48/80 administration. Curiously, 
in the first two minutes after the C48/80 injection, the animals 
presented a hypertensive crisis (without statistical significance) 
and a possible explanation for this is the direct stimulation of 
the hypothalamus hypophysis axis23. The CO reduction could be 
related to the negative inotropic effect of the C48/8024 and could 
explain the CVP trend to increase. In addition, the majority of 
the animals exposed to C48/80 presented cutaneous hyperemia, 
vomits, sphincters liberation, livedo reticularis, cyanosis, ascites 
and intestinal ischemia and distention. 
The histamine-mediated NO production has been ruled 
as one of the most important pathophysiological mechanisms 
in the cardiovascular manifestations during anaphylaxis. It 
was demonstrated that the Nω-nitro-L-arginine-methylester 
(L-NAME), a non-selective NOS inhibitor, reduced the mortality 
in C48/80 or bovine serum albumin-induced anaphylactic shock 
in mice25. Other studies also showed that the L-NAME diminished 
the hypotension and the mortality rates in mice and rats20,26. Despite 
these good results, the NOS inhibitors use to treat the anaphylactic 
shock is not completely accepted since these drugs can reduce 
the CO, increasing the mortality13,14,19. It was demonstrated that 
although the L-NAME had attenuated the hypotension it did not 
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improve cardiac depression in anaphylaxis in dogs14. Furthermore, 
the bronchial production of NO is important to counteract the 
anaphylactic bronchoconstriction, and the NOS inhibition could 
impair this clinical condition13. Indeed, a clinical trial, evaluating 
the NOS inhibition to treat the septic shock, had to be discontinued 
due to increase in mortality27. These concepts seem to discourage 
the NO production inhibition and open a discussion concerning 
the inhibition of the NO effects on the vascular smooth muscle to 
treat the anaphylaxis. In this context, the MB, recognized as a GC 
inhibitor able to abolish the NO/cGMP-dependent smooth muscle 
vasodilatation, emerged as a possible therapeutic strategy. 
The MB has been used in various clinical conditions, 
for example, as an antiseptic for the urinary tract and in the 
methemoglobinemia and malaria treatment. It has also been 
demonstrated that MB can reduce the anaphylactic shock-induced 
hypotension in clinical and experimental studies18,28-32. A previous 
study of our laboratory demonstrated that the MB reduced 
the hypotension and increased the survival time in a model of 
C48/80 induced-anaphylactic shock in rabbits18. In addition, 
some case reports demonstrated that the MB, administered when 
the conventional therapy failed, reversed the hypotension in the 
anaphylactic shock28,31-33. Furthermore, the MB was also effective 
in improving the clinical signs in a different entity, the anaphylaxis 
with no cardiovascular collapse. However, there are a limited 
number of researches addressing the MB as a therapeutic option in 
the anaphylactic shock.
The present investigation showed that the intravenous 
infusion of MB alone caused no changes in the hemodynamic and 
clinical parameters showing that the administered MB dose was 
safe in this experimental model. Our results therefore corroborate 
other clinical data mentioning the MB therapeutic safety, which 
was used to revert catecholamines resistant hypotension in SIRS 
and anaphylaxis15-17,21,29,30. 
The main goal of this study was to evaluate the MB 
effect on prevention and treatment of experimentally induced 
anaphylactic shock. Unfortunately, we showed that the MB did 
not prevent or reverse the C48/80-induced anaphylactic shock in 
this porcine model. In fact, in some time points the MAP of the 
animals with anaphylactic shock treated with MB decreased even 
more than the MAP of the animals from the C48/80 group. On the 
other hand, the C48/80-induced epidermal alterations disappeared 
after the MB infusion. However, the preventive use of MB had no 
or minimal effect on the cutaneous hyperemia evoked by C48/80. 
These results completely oppose our previous study in which 
rabbits and bigger MB doses were used18. 
Concerning the lung circulation, although without 
statistical significance, our results showed a PVR trend to increase 
in the pigs treated with MB after the development of anaphylactic 
shock. These data deserve attention when using MB in the clinical 
setting, because if this increase is not due to a right ventricular 
dysfunction, it can be consequence of an undesirable lung 
hypertension, which was not observed in heart surgery patients 
infused with MB to treat vasoplegic syndrome29. 
Despite our data, the clinical manifestations improvement 
brings some optimism and does not allow excluding the MB as 
a possible therapeutic option in the anaphylactic shock. New 
studies, including bigger sample size, greater MB doses, longer 
time observation, different experimental models, therapeutic 
combination with catecholamines and/or crystalloid infusions, can 
provide better results and even help to define safe and effective 
procedures for treating anaphylactic shock.
Conclusion
Despite our data, the clinical manifestations improvement 
brings some optimism and does not allow excluding the methylene 
blue as a possible therapeutic option in the anaphylactic shock.
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